Methods for treating pompe disease

A Pompe disease and fusion protein technology, applied in the field of treatment of Pompe disease, can solve problems such as no significant success, and achieve the effect of cost-effectiveness, potential and simple method

Inactive Publication Date: 2010-01-27
BIOMARIN PHARMA INC
View PDF7 Cites 8 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0005] Drug therapy strategies, diet control, and bone marrow transplantation have been employed as treatments for Pompe disease, but without significant success

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Methods for treating pompe disease
  • Methods for treating pompe disease
  • Methods for treating pompe disease

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0091] Example 1: Production of recombinant wild-type GAA and GILT-tagged GAA

[0092] plasmid

[0093] DNA encoding full-length wild-type human GAA was isolated and inserted into an expression vector for production of recombinant human GAA. The DNA cassette encoding amino acids 1-952 of fully human GAA (hereafter referred to as "cassette 635") was derived from IMAGE clone 4374238 (OpenBiosystems) and was derivatized using the following PCR primers:

[0094] GAA13: 5'-GGAATTCCAACCATGGGAGTGAGGCACCCGCCC (SEQ ID NO: 1) and

[0095] GAA27: 5'-GCTCTAGACTAACACCAGCTGACGAGAAACTGC (SEQ ID NO: 2).

[0096] Cassette 635 was digested with EcoRI and Xbal, inactivated by treatment with Klenow DNA polymerase, and ligated into the Klenow-treated HindIII site of the expression vector pCEP4 (Invitrogen), resulting in plasmid p635. Hereinafter, ZC-635 refers to wild-type untagged GAA protein.

[0097] A DNA cassette for the production of recombinant GILT-tagged GAA ZC-701 (hereinafter...

Embodiment 2

[0110] Example 2: Affinity of GILT-tagged GAA for CI-MPR

[0111] Binding affinity utilization of GILT-tagged GAA ZC-701 for CI-MPR Surface plasmon resonance assay (surface plasmon resonance assay) to determine. Two biotinylated and His-tagged recombinant proteins (containing wild-type CI-MPR domain 10-13 and one point mutation variant) were formed, respectively, according to standard molecular techniques. Schematic representation of the two recombinant proteins as Figure 3A shown. Plasmid p1288 contains the IGF-II signal peptide followed by: a poly-His (poly-His) tag; a biotin AS domain; and a sequence encoding wild-type CI-MPR domains 10-13. Plasmid p1355 contains the IGF-II signal peptide followed by: a poly-His (poly-His) tag; a biotin AS domain; and a CI-MPR encoding a point mutation I1572T that effectively reduces the affinity of the receptor for IGF-II Sequences of domains 10-13. The specific DNA and amino acid sequences associated with these two recombinant pr...

Embodiment 3

[0130] Example 3: Analysis of N-linked oligosaccharides shows that ZC-701 lacks M6P

[0131] N-linked oligosaccharide analysis was performed to determine the oligosaccharide profile of ZC-701 using PNGase deglycosylation followed by a combination of HPLC analysis with fluorescence detection (Blue Stream Laboratories).

[0132] Cleavage of N-linked sugars (carbohydrates) from glycoprotein samples was performed by N-glycanase at a ratio of 1:100 (enzyme to substrate) using approximately 100 μg of protein per sample. Once released, glycans were extracted using cold ethanol and dried by centrifugation. The recovered oligosaccharides were labeled with 2-aminobenzamide (2-AB) under acidic conditions in the presence of sodium cyanoborohydride. After the derivatization step, by The S sample filter catheter (Prozyme) removes excess dye and other reactive reagents remaining in the sample.

[0133] Analysis of N-linked oligosaccharides by HPLC-FLD used the following conditions: mob...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The present invention provides methods for treating Pompe disease in a subject by administering to the subject a therapeutically effective amount of a fusion protein which includes human acid alpha-glucosidase (GAA), or a fragment thereof, and a lysosomal targeting domain. The lysosomal targeting domain binds the human cation-independent mannose-6-phosphate receptor in a mannose-6-phosphate-independent manner.

Description

[0001] References to related applications [0002] This application claims U.S. Provisional Patent Application No. 60 / 900,187, filed February 7, 2007, U.S. Provisional Patent Application No. 60 / 879,255, filed January 5, 2007, filed November 13, 2006 Priority to US Provisional Patent Application No. 60 / 858,514, the contents of each of which are hereby incorporated in their entirety. This application is also related to US Patent Application No. 11 / 057,058, filed February 10, 2005, which is hereby incorporated by reference in its entirety. technical field [0003] The present invention relates to methods and compositions for the treatment of Pompe disease. More specifically, the present invention relates to a therapy for the treatment of Pompe disease by targeting acid alpha-glucosidase to lysosomes in a mannose-6-phosphate-independent manner method. Background technique [0004] Pompe disease is an autosomal recessive genetic disorder (gene disorder) caused by deficiency or...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61P3/00A61K47/48
Inventor 乔纳森·勒博茨约翰·马加
Owner BIOMARIN PHARMA INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap